Fulltext

Nifurtimox-Eflornithine Combination Therapy for Second-Stage Gambiense Human African Trypanosomiasis: Médecins Sans Frontières Experience in the Democratic Republic of the Congo

Alirol, Emilie ; Schrumpf, David ; Amici Heradi, Josué ; Riedel, Andrea ; de Patoul, Catherine ; Quere, Michel ; Chappuis, François

In: Clinical Infectious Diseases, 2013, vol. 56, no. 2, p. 195-203

Zum persönliche Liste hinzufügen
    Titel
    • Nifurtimox-Eflornithine Combination Therapy for Second-Stage Gambiense Human African Trypanosomiasis: Médecins Sans Frontières Experience in the Democratic Republic of the Congo
    Autor
    • Alirol, Emilie. Division of International and Humanitarian Medicine, University Hospitals of Geneva
    • Schrumpf, David. Division of International and Humanitarian Medicine, University Hospitals of Geneva
    • Amici Heradi, Josué. Médecins Sans Frontières, Operational Centre Geneva, Switzerland
    • Riedel, Andrea. Médecins Sans Frontières, Operational Centre Geneva, Switzerland
    • de Patoul, Catherine. Médecins Sans Frontières, Operational Centre Geneva, Switzerland
    • Quere, Michel. Médecins Sans Frontières, Operational Centre Geneva, Switzerland
    • Chappuis, François. Division of International and Humanitarian Medicine, University Hospitals of Geneva
    Dokumententyp
    • Postprint
    Sprache
    • Englisch
    Veröffentlicht in
    • Clinical Infectious Diseases, 2013, vol. 56, no. 2, p. 195-203. Oxford University Press
    Andere elektronische Ausgabe
    OAI-PMH-ID
    • oai:doc.rero.ch:290169
    Summary
    Since 2009, nifurtimox-eflornithine combination therapy (NECT) has raised great hopes for the treatment of second-stage human African trypanosomiasis. Data from the first 18 months of NECT use in Médecins Sans Frontières programs in the Democratic Republic of the Congo confirm its good safety profile, especially among children